Study of stem cell transplant after chemo for children with germ cell tumors
Treatments studied
Part of Cancer clinical trials.
This study looks at how well a stem cell transplant works after a specific combination of chemotherapy drugs (gemcitabine, docetaxel, melphalan, and carboplatin) in children and young adults up to age 21 whose germ cell tumors have come back or not responded to treatment. It may help doctors understand who benefits most from this approach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 1 month and 21 years old.
- You have a germ cell tumor (seminoma or nonseminoma) that has come back or not responded to treatment.
- You have already had or will have a stem cell transplant using the chemotherapy drugs gemcitabine, docetaxel, melphalan, and carboplatin (GemDMC).
- You are willing to follow the study's treatment and follow-up schedule.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial studies the best “conditioning” chemotherapy plan before an allogeneic stem cell transplant for children with AML. It may help improve outcomes by testing an approach for kids who are ready for transplant after relapse or specific high-risk features.
This study looks at how to manage germ cell tumors in children and young adults using careful monitoring for some patients and chemotherapy for others. It aims to see whether these approaches can control the cancer while avoiding unnecessary treatment when possible.
This trial tests a combination of drugs (thiotepa, cyclophosphamide, clarithromycin, and cytarabine) before a stem cell transplant. It is for people with certain types of blood cancer who have responded well to earlier treatment.
This Phase 2 study tests intensive treatment (high-dose “consolidation”) followed by rescue with your own stem cells for high-risk neuroblastoma. It may help patients keep the cancer from coming back after it has improved or stabilized from initial chemotherapy.
This study looks at “molecular” (DNA-related) features of germ cell tumors in children and teens. It also follows patients over time, which can help researchers understand tumor patterns and improve future care.
This trial tests a second-line high-dose chemotherapy for germ cell tumors that have come back after initial treatment. It may be an option for patients whose cancer progressed after 3–4 cycles of standard platinum-based chemo.
Hear when a new Gemcitabine trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.